Deborah Assayag1, Eric Vittinghoff2, Christopher J Ryerson3, Elisabetta Cocconcelli4, Roberto Tonelli4, Xiaowen Hu5, Brett M Elicker6, Jeffrey A Golden7, Kirk D Jones8, Talmadge E King7, Laura L Koth7, Joyce S Lee7, Brett Ley7, Anthony K Shum7, Paul J Wolters7, Jay H Ryu5, Harold R Collard7. 1. Department of Medicine, University of California San Francisco, San Francisco, CA, United States. Electronic address: Deborah.Assayag@mail.mcgill.ca. 2. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States. 3. Department of Medicine, University of British Columbia, Vancouver, Canada. 4. School of Medicine, University of Modena, Modena, Italy. 5. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States. 6. Department of Radiology, University of California San Francisco, San Francisco, CA, United States. 7. Department of Medicine, University of California San Francisco, San Francisco, CA, United States. 8. Department of Pathology, University of California San Francisco, San Francisco, CA, United States.
Abstract
BACKGROUND: Forced vital capacity (FVC) is a key measure of disease severity in patients with idiopathic pulmonary fibrosis (IPF) and is an important clinical trial endpoint. We hypothesize that reversible airflow limitation co-exists in a subgroup of patients with IPF, and that bronchodilator use will improve the performance characteristics of FVC. METHODS: IPF patients with pre and post-bronchodilator spirometry testing performed were identified from two tertiary referral cohorts. The difference between pre and post-bronchodilator FVC (intra-test difference) was calculated. The test characteristics of pre and post-bronchodilator FVC change over time (inter-test difference) were assessed in patients with sequential spirometry, and were used to generate sample size estimates for hypothetical clinical trials using change in FVC as the primary endpoint. RESULTS: There were 551 patients, contributing 967 unique spirometry tests. The mean intra-test increase in FVC with bronchodilator use was 0.04 L (2.71 vs. 2.75 L, p < 0.001). Reversible airflow limitation (increase in FEV1 or FVC of ≥12% and ≥200 mL) occurred in 9.1% of patients. The inter-test difference in change in FVC over time were equivalent for pre and post-bronchodilator (p = 0.65), leading to similar sample size estimates in a hypothetical clinical trial using change in FVC as the primary endpoint. CONCLUSION: Approximately one in ten patients with IPF has physiological evidence of reversible airflow limitation, and bronchodilator use in these patients may improve the assessment of disease progression based on FVC change over time. Bronchodilator use does not appear to meaningfully impact the precision of FVC as an endpoint in clinical trials.
BACKGROUND: Forced vital capacity (FVC) is a key measure of disease severity in patients with idiopathic pulmonary fibrosis (IPF) and is an important clinical trial endpoint. We hypothesize that reversible airflow limitation co-exists in a subgroup of patients with IPF, and that bronchodilator use will improve the performance characteristics of FVC. METHODS: IPF patients with pre and post-bronchodilator spirometry testing performed were identified from two tertiary referral cohorts. The difference between pre and post-bronchodilator FVC (intra-test difference) was calculated. The test characteristics of pre and post-bronchodilator FVC change over time (inter-test difference) were assessed in patients with sequential spirometry, and were used to generate sample size estimates for hypothetical clinical trials using change in FVC as the primary endpoint. RESULTS: There were 551 patients, contributing 967 unique spirometry tests. The mean intra-test increase in FVC with bronchodilator use was 0.04 L (2.71 vs. 2.75 L, p < 0.001). Reversible airflow limitation (increase in FEV1 or FVC of ≥12% and ≥200 mL) occurred in 9.1% of patients. The inter-test difference in change in FVC over time were equivalent for pre and post-bronchodilator (p = 0.65), leading to similar sample size estimates in a hypothetical clinical trial using change in FVC as the primary endpoint. CONCLUSION: Approximately one in ten patients with IPF has physiological evidence of reversible airflow limitation, and bronchodilator use in these patients may improve the assessment of disease progression based on FVC change over time. Bronchodilator use does not appear to meaningfully impact the precision of FVC as an endpoint in clinical trials.
Authors: R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger Journal: Eur Respir J Date: 2005-11 Impact factor: 16.671
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: V Cottin; H Nunes; P-Y Brillet; P Delaval; G Devouassoux; I Tillie-Leblond; D Israel-Biet; I Court-Fortune; D Valeyre; J-F Cordier Journal: Eur Respir J Date: 2005-10 Impact factor: 16.671
Authors: Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Talmadge E King; Sharon Safrin; Karen M Starko; Kevin K Brown; Paul W Noble; Ganesh Raghu; David A Schwartz Journal: Chest Date: 2005-01 Impact factor: 9.410
Authors: H Taniguchi; M Ebina; Y Kondoh; T Ogura; A Azuma; M Suga; Y Taguchi; H Takahashi; K Nakata; A Sato; M Takeuchi; G Raghu; S Kudoh; T Nukiwa Journal: Eur Respir J Date: 2009-12-08 Impact factor: 16.671
Authors: Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: Ganesh Raghu; Kevin K Brown; Williamson Z Bradford; Karen Starko; Paul W Noble; David A Schwartz; Talmadge E King Journal: N Engl J Med Date: 2004-01-08 Impact factor: 91.245
Authors: Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2003-06-05 Impact factor: 21.405
Authors: Omar S Usmani; Martyn F Biddiscombe; Shuying Yang; Sally Meah; Eunice Oballa; Juliet K Simpson; William A Fahy; Richard P Marshall; Pauline T Lukey; Toby M Maher Journal: Respir Res Date: 2018-02-06